Targeting the PI3K-Akt pathway in kidney cancer

Jin Young Park, Pei Yin Lin, Robert H Weiss

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Kidney cancer, or renal cell carcinoma, is a relatively rare malignancy but is metastatic at diagnosis in a third of patients; metastatic disease has a dismal prognosis. Conventional chemotherapy has been woefully inadequate, thus novel targets for 'designer' therapies are being actively evaluated. The PI3K-Akt signaling cascade, owing to its dual role in both survival and mitogenic signaling, is in theory an ideal therapeutic target for this disease, but may also represent its fatal flaw. Thus, largely due to toxicity issues, no PI3K or Akt inhibitors are currently ready for clinical application. In this review, we discuss PI3K-Akt inhibitors as well as inhibitors of pathways and targets both immediately up- and downstream of this cascade, many of which show promise in the clinic.

Original languageEnglish (US)
Pages (from-to)863-870
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume7
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Kidney Neoplasms
Phosphatidylinositol 3-Kinases
Renal Cell Carcinoma
Drug Therapy
Survival
Therapeutics
Neoplasms

Keywords

  • Akt
  • Inhibitors
  • PI3K
  • Receptor tyrosine kinase
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Targeting the PI3K-Akt pathway in kidney cancer. / Park, Jin Young; Lin, Pei Yin; Weiss, Robert H.

In: Expert Review of Anticancer Therapy, Vol. 7, No. 6, 06.2007, p. 863-870.

Research output: Contribution to journalArticle

Park, Jin Young ; Lin, Pei Yin ; Weiss, Robert H. / Targeting the PI3K-Akt pathway in kidney cancer. In: Expert Review of Anticancer Therapy. 2007 ; Vol. 7, No. 6. pp. 863-870.
@article{729e3cda0dad407e82beaee077c5aa7a,
title = "Targeting the PI3K-Akt pathway in kidney cancer",
abstract = "Kidney cancer, or renal cell carcinoma, is a relatively rare malignancy but is metastatic at diagnosis in a third of patients; metastatic disease has a dismal prognosis. Conventional chemotherapy has been woefully inadequate, thus novel targets for 'designer' therapies are being actively evaluated. The PI3K-Akt signaling cascade, owing to its dual role in both survival and mitogenic signaling, is in theory an ideal therapeutic target for this disease, but may also represent its fatal flaw. Thus, largely due to toxicity issues, no PI3K or Akt inhibitors are currently ready for clinical application. In this review, we discuss PI3K-Akt inhibitors as well as inhibitors of pathways and targets both immediately up- and downstream of this cascade, many of which show promise in the clinic.",
keywords = "Akt, Inhibitors, PI3K, Receptor tyrosine kinase, Renal cell carcinoma",
author = "Park, {Jin Young} and Lin, {Pei Yin} and Weiss, {Robert H}",
year = "2007",
month = "6",
doi = "10.1586/14737140.7.6.863",
language = "English (US)",
volume = "7",
pages = "863--870",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Targeting the PI3K-Akt pathway in kidney cancer

AU - Park, Jin Young

AU - Lin, Pei Yin

AU - Weiss, Robert H

PY - 2007/6

Y1 - 2007/6

N2 - Kidney cancer, or renal cell carcinoma, is a relatively rare malignancy but is metastatic at diagnosis in a third of patients; metastatic disease has a dismal prognosis. Conventional chemotherapy has been woefully inadequate, thus novel targets for 'designer' therapies are being actively evaluated. The PI3K-Akt signaling cascade, owing to its dual role in both survival and mitogenic signaling, is in theory an ideal therapeutic target for this disease, but may also represent its fatal flaw. Thus, largely due to toxicity issues, no PI3K or Akt inhibitors are currently ready for clinical application. In this review, we discuss PI3K-Akt inhibitors as well as inhibitors of pathways and targets both immediately up- and downstream of this cascade, many of which show promise in the clinic.

AB - Kidney cancer, or renal cell carcinoma, is a relatively rare malignancy but is metastatic at diagnosis in a third of patients; metastatic disease has a dismal prognosis. Conventional chemotherapy has been woefully inadequate, thus novel targets for 'designer' therapies are being actively evaluated. The PI3K-Akt signaling cascade, owing to its dual role in both survival and mitogenic signaling, is in theory an ideal therapeutic target for this disease, but may also represent its fatal flaw. Thus, largely due to toxicity issues, no PI3K or Akt inhibitors are currently ready for clinical application. In this review, we discuss PI3K-Akt inhibitors as well as inhibitors of pathways and targets both immediately up- and downstream of this cascade, many of which show promise in the clinic.

KW - Akt

KW - Inhibitors

KW - PI3K

KW - Receptor tyrosine kinase

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=34347244544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347244544&partnerID=8YFLogxK

U2 - 10.1586/14737140.7.6.863

DO - 10.1586/14737140.7.6.863

M3 - Article

C2 - 17555396

AN - SCOPUS:34347244544

VL - 7

SP - 863

EP - 870

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 6

ER -